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ABsTrAcT:                                                                                                                         
The incidence of gestational diabetes mellitus (GDM) increases globally, including Poland. Considering serious consequences 
of gestational diabetes for both mother and fetus, screening for this disorder is an obligatory element of managing pregnant 
woman. The pathogenesis of gestational diabetes is not yet thoroughly explained. However, it is insulin resistance and chronic 
subclinical inflammatory process which are considered to be major factors responsible for the development of GDM. These 
two states are triggered mainly by secretion of proinflammatory cytokines and by abnormal function of adipose tissue. 
The study reviews the literature on selected hormones and cytokines whose role in the GDM pathogenesis has been already 
confirmed  as well as on those proteins whose role is either not yet fully understood or which may possibly participate 
in GDM development. Owing to the fact that underlying mechanisms of GDM are, in general, similar to the mechanisms 
responsible for metabolic disorders such as diabetes mellitus type 2 or obesity, in this review we focus first on the role 
these molecules play in pathogenesis of metabolic disorders and then present current state of knowledge on their action 
in gestational diabetes development. The review presents: TNF alpha, adipokines — adiponectin and leptin and relatively 
newly discovered proteins: fetuin A, periostin, angiopoietin-like protein 8 or high mobility group box.
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INTrODUcTION
Gestational diabetes mellitus (GDM) is a glucose in-
tolerance disorder with onset or first recognition during 
pregnancy, which, however, does not meet the criteria of 
diabetes mellitus for the general population [1, 2]. Based 
upon available publications, the prevalence of GDM varies 
widely — from 1% to 22% of pregnant women, depend-
ing on the examined group of patients and adopted GDM 
diagnostic criteria. Its frequency increases globally [1–8]. 
Screening for GDM is an obligatory element of managing 
pregnant woman in many countries, including Poland. The 
reason for this is that GDM is related to several short and 
long-term complications.
Of special concern is the fact that, in the long term, there 
is a higher risk of developing diabetes mellitus type 2 in the 
future in both mother affected by GDM and in her offspring. 
In the woman with a history of GDM, the incidence of DM2 is 
estimated from 3% to even over 90%, depending mainly on 
the study design and observation time. This is true for both 
lean and obese women. 
Considering the growing incidence of GDM and the 
complications related to this, it is not surprising that big 
efforts are made to fully understand its pathogenesis. Un-
derstanding GDM background could facilitate predicting its 
development in  pregnant women and lead to the introduc-
tion of new treatment methods. Thus, the aim of this study 
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was to review the literature on selected hormones and 
cytokines — on those whose role in the GDM pathogenesis 
has been already confirmed as well as on those whose role 
is either not yet fully understood or which may possibly 
participate in GDM development. Owing to the fact that 
underlying mechanisms of GDM are in general, similar to 
the mechanisms responsible for metabolic disorders such 
as DM2 or obesity (see below), in this review we focus first 
on the role of these molecules in pathogenesis of metabolic 
disorders and then present current state of knowledge on 
their action in GDM development. 
Pathogenesis of gestational diabetes mellitus — 
general information
Although pathogenesis of GDM is not yet thoroughly 
explained, it is insulin resistance (IR) and chronic subclinical 
inflammatory process which are considered major factors 
responsible for its development. They are also the key patho-
genetic mechanisms of obesity and other metabolic disorders, 
including DM2, as mentioned above. Inflammation and IR are 
triggered by abnormal activity of adipose tissue. The latter is 
a source of inflammatory mediators. It is also a place of interac-
tion between adypocytes and immunocompetent cells. The 
studies on animal model and in humans demonstrate that 
adypocytes of obese individuals secrete proinflammatory 
cytokines, which, in turn, enhance infiltration of macrophages 
in adipose tissue. Furthermore, adipose tissue secretes adi-
pokines, which also play a vital role in the development of IR 
and metabolic disorders such as DM2 or GDM [9]. 
Tumor necrosis factor alpha — proinflammatory 
cytokine
Tumor necrosis factor alpha (TNF alpha) is a proinflam-
matory cytokine, which has a major role in the develop-
ment of IR and DM2 [10]. It is produced by monocytes and 
macrophages in the adipose tissue [11]. It has proapoptotic 
activity, affects cell differentiation and recruitment. Acting 
via tumor necrosis factor receptor 1 (TNFR-1), it activates 
immunocompetent cells to spread inflammatory process. It 
also induces oxidative stress. Oxidative stress alongside 
inflammation promote cells degeneration [10, 12]. Further-
more, TNF alpha stimulates prostaglandins synthesis by 
inducing cyclooxygenase 2. By activating several caspases, 
it enhances apoptosis of the inflammed cells [13]. The stud-
ies demonstrate excessive expression of TNF alpha in the 
adipose tissue in obese individuals compared to lean sub-
jects [14]. TNF alpha promotes IR by suppressing tyrosin 
phosphorylation of insulin receptor and its substrate-insulin 
receptor substrate-1 (IRS-1) because it inhibits action of 
tyrosine kinase [15]. Furthermore, it diminishes expression 
of glucose transporter type 4 (GLUT 4) in the adipose tissue, 
skeletal muscles and cardiac muscle. Proinflamamtory activ-
ity of TNF alpha in beta cells of the pancreas plays a vital role 
in their apoptosis, contributing thereby to diabetes mellitus 
development [10]. Administration of TNF-alpha antagonist 
etanercept in obese human subjects with metabolic syn-
drome decreased fasting glucose in 6-month observation 
time but did not change insulin sensitivity [16]. 
Based upon the available literature, more TNF alpha is 
secreted in pregnancy, particularly in third trimester. This 
is true for both normal pregnancy and for the pregnancy 
complicated by GDM [17, 18]. Highest levels of TNF alpha are 
found in GDM. Xu performed a retrospective meta-analysis 
of 27 trials where concentration of TNF alpha in pregnancy 
was evaluated. Significantly higher TNF alpha values were 
found in women with GDM when compared to pregnant 
women with normoglycemia. In the studies, the differences 
in TNF alpha concentrations were significant also after ruling 
out the influence of the body mass [4]. 
In pregnancy, TNF alpha is secreted not only by adipose 
tissue but also by placenta. It seems that excessive amount 
of TNF alpha in GDM originates from placental secretion 
rather than from adipose tissue production. According to 
Kirwan, gestational insulin resistance and impaired glucose 
tolerance are mainly due to elevated TNF alpha (and to less 
extent to higher leptin and cortisol levels), rather than to 
excessive secretion of placental hormones such as prolactin, 
human chorionic gonadotropin (hCG) or human placental 
lactogen (HPL) as it was previously thought [19]. 
Adipokines — leptin and adiponectin
Adipokines are hormones secreted by adipose tissue; 
their impaired secretion is related to several metabolic disor-
ders such as insulin resistance, obesity, DM2, cardiovascular 
diseases or GDM. 
Of these, leptin has been examined best to this day. Apart 
from the role in the metabolic diseases development, it plays 
a role in the puberty and in angiogenesis [20]. Leptin is called 
a “satiety hormone” because it regulates food intake and en-
ergy expenditure. It acts via leptin receptors which are found 
in the hypothalamus [1, 21]. Its secretion is regulated, among 
others, by insulin and cortisol concentrations [22]. A reverse 
correlation was found between leptin and insulin sensitiv-
ity. In obese individuals, leptin’s concentration is elevated 
and its exogenous supplementation does not lead to body 
mass reduction, thus suggesting resistance to this hormone 
in fat individuals. At the same time, body mass reduction 
results in leptin blood level decline and insulin sensitivity in-
crease [23]. It is postulated that hyperleptinemia suppresses 
insulin-dependent glucose transport to adipocytes [1, 24]. 
Furthermore, it may directly impair glucose secretion by beta 
cells of the pancreas [1, 25]. Obese individuals without insulin 
resistance have lower leptin levels compared to fat subjects 
in whom insulin resistance is present [26].
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In physiologic pregnancy as well as in the pregnancy 
complicated by GDM, leptin’s concentration increases 
gradually with the highest values detected in 28th week of 
gestation and is followed by plateau, to decrease eventu-
ally before delivery [22]. In pregnancy, leptin is secreted 
not only by adipose tissue but also by placenta. Its con-
centration in GDM is higher than in normoglycemic preg-
nancy and higher than in pregnant-diabetes-mellitus-type 
1 patients. However, the data on the main source of leptin 
in GDM — whether it is adipose tissue or placenta — are 
contradictory. The majority of studies prove positive cor-
relation between leptin’s concentration with body weight 
and body mass index (BMI). It is true for both pregnant and 
non-pregnant women [22, 27]. 
Adiponectin is an adipokine with anti-inflammatory 
activity. It inhibits lipopolysaccharide (LPS)-stimulated 
TNF-alpha production by macrophages, enhances secre-
tion of anti-inflammatory Il-10, and stimulates the action of 
macrophages M2. The latter are responsible for the phago-
cytosis of apoptotic cells. Enhancement of apoptotic cells 
clearance by macrophages M2 protects the organism from 
systemic inflammation [28, 29]. Adiponectin expression 
in adipose tissue is diminished by TNF alpha and Il-6. This 
explains why adiponectin’s concentration declines in the 
states related to subclinical inflammation such as obesity, 
IR or DM2 [28–30]. Adiponectin’s concentration is also lower 
in the smokers, in cardiovascular disease and in polycystic 
ovary syndrome (PCOS) [31]. Besides, its low concentrations 
are found in selected malignant neoplasms [32]. 
Adiponectin sensitizes the tissues to insulin indirectly 
due to the anti-inflammatory action mentioned above. It 
also increases insulin sensitivity by stimulating glucose 
uptake in skeletal muscles and by diminishing hepatic glu-
coneogenesis. Exogenous administration of adiponectin to 
laboratory animals decreases IR in them [33]. Adiponectin is 
believed to suppress development of atherosclerosis, fatty 
liver disease and liver fibrosis [28, 34]. 
In pregnancy, adiponectin is secreted mainly by adipose 
tissue. It remains controversial whether placenta could be 
an additional source of this hormone [1, 32]. Generally, 
pregnancy is regarded as a state of physiologic hypoadi-
ponectinemia. In fact, several studies proved decline of 
adiponectin concentration in both physiologic pregnancy 
and in GDM [30, 32, 35]. Williams found that low adiponec-
tin concentration in early pregnancy is a predictor of GDM 
development in the third trimester regardless woman’s age, 
pregravid obesity or familial history of DM2 [31].
Angiopoietin-like protein 8 
Angiopoietin-like protein 8 (ANGPTL8), also known as 
lipasin or betatrophin, is a recently discovered hormone. It 
is produced mainly by the liver and in adipose tissue [36, 
37]. It takes part in glucose and lipids homeostasis – inhibits 
lipoprotein lipase activity and, according to some authors, 
also stimulates pancreas beta cells proliferation in IR states. It 
is postulated that liver is the main source of this protein [38, 
39]. The liver expression of ANGPTL8 is elevated in laboratory 
animals with IR. However, beta cells growth followed by en-
hanced insulin secretion due to ANGPTL8 supplementation 
which was found in the animals was not confirmed in hu-
mans [39, 40]. Higher ANGPTL8 concentrations were found 
in obese individuals and in DM2 patients [36]. In the study 
by Wang, in women with PCOS and with IR, higher concen-
trations of ANGPTL8 were found in comparison to healthy 
women. Hormone’s concentration correlated positively with 
BMI, waist to hip ratio (WHR), triglycerides (TG), total choles-
terol (TC), free androgen index (FAI), and homeostasis model 
assessment for insulin resistance (HOMA-IR). Furthermore, 
hepatocytes’ stimulation by insulin (EHC, hyperinsulemic 
euglycemic clamp) enhanced ANGPTL8 expression, while 
metformin or rosiglitason therapy declined the hormone’s 
level [41]. 
The majority of studies point the role of ANGPTL8 in the 
development of metabolic disorders. Yet, there are authors 
who deny these observations. For example, Gomez-Ambrosi 
found decreased ANGPTL8 level in DM2 and in obesity. In 
this study, the lowest ANGPTL8 concentrations were found 
in subjects where obesity was associated with IR [39]. 
It has been suggested that significant discrepancies in 
ANGPTL8 concentrations among different studies may be due 
to the fact that different kits were used in these trials. Differ-
ent kits measure different betatrophin species — full-length 
protein, C-terminal fragments or N-terminal fragments [42]. 
Physiologically, full-length protein is cleaved from pro-pro-
tein, releasing C-terminal fragment. This post-translational 
regulation of betatrophin concentration determines the 
presence of different betatrophin fragments in serum. Ac-
cording to Fu, it seems that kits with C-terminal antibodies 
recognize both C-fragments and full-length protein. On the 
other hand, ELISA kits that measure N-terminal ELISA tests, 
measure full-length protein only. Thus, the kits that measure 
C-fragments will give higher betatorophin values than the 
kits measuring N-terminals. The discrepancies between the 
results obtained in different trials can be also due to differ-
ent time of blood collection (fasting vs postprandial state). 
Besides, stronger expression of ANGPTL8 is caused by insulin, 
cold or feeding [37, 38, 42]. Weaker betarophin expression is 
seen in starving and in other states of enhanced lipolysis [37]. 
The studies point to elevated betatrophin values in preg-
nancy [38, 40]. In the study by Perez, ANGPTL8 concentration 
in normal pregnancy was approximately ten times higher 
than in non-pregnant women [38]. Trebotic found signifi-
cantly higher hormone concentrations in pregnancy with 
the highest values in pregnancies complicated by GDM 
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[40]. On the other hand, Martinez–Perez also confirmed 
higher betatrophin values in pregnancy but its values did 
not differ significantly between normoglycemic pregnancy 
and pregnancy complicated by GDM. In the study, in all 
pregnant women, the highest values were found in the 
first trimester with a gradual decline during pregnancy. It is 
worth mentioning, that betatrophin concentration is higher 
in umbilical-cord blood than in mother’s blood, suggesting 
its role in fetal development [38].
Periostin
Periostin is a protein which was primarily isolated from 
mice osteoblasts. It is found in the tissues rich in collagen such 
as tendons, ligaments, cardiac valves or cornea [43]. Due to 
its effect on mesenchymal cells, it plays a role in bone and 
teeth development [44]. It participates in the pathogenesis of 
neoplasms, arthritis, atherosclerosis or inflammatory diseases 
[43, 44]. A relation was found between periostin concen-
tration and metabolic diseases as periostin enhances c-Jun 
N-terminal kinase (JNK)-dependent suppression of fatty acids 
oxidation in the liver. Higher glucose concentrations enhance 
periostin expression [44]. In the study by Luo, significantly 
higher periostin concentrations were found in obese patients 
and in patients with DM2 compared to healthy individu-
als. The highest concentrations were found in obese patients 
with concomitant DM2. Furthermore, a positive correlation 
was stated between periostin and TG and TC and negative 
— between periostin and HDL. The TG concentration was 
an independent factor affecting periostin level after ruling out 
age, sex and BMI value of the examined patients. In the study, 
positive correlation between periostin and TNF alpha and 
Il-6 was found [43]. Since periostin promotes liver steatosis, 
it is postulated that it could serve as a marker of NAFLD as its 
concentrations were significantly higher in NAFLD patients 
compared to healthy controls [44, 45]. Satirapoj found higher 
periostin concentrations in the urine of DM2 patients, even 
before the albuminuria onset [46].
In the available literature no articles were found on the 
relation between periostin concentration and GDM. Con-
sidering, however, a strong pathogenetic relation between 
GDM and metabolic disorders such as obesity or DM2 where 
periostin concentration is elevated, it can be expected that 
its concentration in GDM will be elevated, too. 
The studies show the role of periostin in embryo im-
plantation and development. In the study by Freis, it was 
suggested that periostin could serve as an early prognostic 
marker of miscarriage, as its rise in miscarriage is observed 
even before the decline in beta hCG level is detected [47]. 
Fetuin A
Fetuin A is a multifunctional glycoprotein produced 
mainly in the liver [48, 49]. It plays a role in blood-vessels cal-
cification and in bone metabolism. Its higher concentrations 
are found in IR related to PCOS or DM2 [49]. Furthermore, 
a positive correlation was found between fetuin A level and 
the risk of developing DM2 in women. The role of fetuin A in 
metabolic disorders is due to insulin receptor inhibition by 
interacting in thyrosin kinase action [50]. In skeletal mus-
cles and in the liver, a direct inhibitory effect of fetuin A on 
autophosphorylation of insulin receptor was detected [49]. 
The study on animals showed that lack of fetuin A protects 
them against age-related loss of insulin sensitivity [50]. It 
was also found that DM2 patients with higher glycated 
hemoglobin (HbA1C) values (> = 7.0%) had higher fetuin 
A concentrations than patients with lower HbA1C levels (< 
6.5%), suggesting the influence of chronic hyperglycemia on 
fetuin A concentration (51). However, following Iydir, there 
are also studies which deny any relation between DM2 and 
fetuin A concentration [49].
The results on fetuin A concentration in normal preg-
nancy and in pregnancy complicated by GDM are contradic-
tory. Kalabay showed higher fetuin A concentration in GDM. 
He also confirmed positive correlation between fetuin A and 
C-peptyde level [52]. Similarly, Iydir found higher fetuin 
A concentration in GDM when compared to healthy women. 
Furthermore, he stated a correlation between HbA1C and 
fetuin A level and between fetuin A and TG or TC level [49]. 
On the other hand, Farhan did not show any differences in 
fetuin A concentration in the third trimester between nor-
moglycemic women and women in whom in the course of 
OGTT GDM was detected [48]. 
High mobility group box 1
High mobility group box 1 (HMBG-1) is a protein which 
migrates quickly during electrophoresis and thus was 
named for this feature. It is a non-histone protein respon-
sible for the maintenance of nucleosome structure in the 
cell nucleus. It takes part in the regulation of genes’ tran-
scription and in the repairing of chromosomal DNA [53, 
54]. HMBG-1 is released from damaged cells, it can be also 
secreted to the extracellular space after cell activation by 
immunocompetent cells. Monocytes and macrophages, 
stimulated by cytokines such as IFN-y, TNF alpha or Il-1, 
secrete actively HMBG-1 [54]. 
 It plays a role in inflammations - both infectious and 
non-infectious. For example, it promotes the development 
of septic shock, systemic lupus erythematosus, dissemi-
nated intravascular coagulation, cardiovascular diseases or 
it is involved in the endothelium dysfunction. The studies 
confirm that HMBG-1 participates in IR development [53]. 
Arrigo showed extremely high HMBG-1 values in obese 
children, and its concentration was in the positive correla-
tion with other proinflammatory cytokines such as TNF 
alpha, Il-6, Il-18 [55]. 
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A positive correlation was found in pregnant women 
between HMBG-1 concentration and HOMA-IR, glucose 
concentrations in OGTT and with pre-gravid BMI value. 
HMBG-1 was an independent risk factor of GDM [53]. The 
fact that HMBG-1 is a marker of inflammatory process and 
that it is elevated in GDM, indirectly confirms the role of 
inflammation in GDM development. 
cONcLUsION
Considering the growing incidence of GDM and the con-
sequences related to this, it is necessary to fully understand 
its pathogenesis – the studies on relatively newly discovered 
proteins such as fetuin A, periostin, angiopoietin-like protein 
8 or high mobility group box 1 may provide new insights 
into this matter.
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